Song Fuxi, Ye Chunmiao, Qi Feng, Zhang Ping, Wang Xuexiang, Lü Yanfeng, Fernandez-Escobar Alejandro, Zheng Chao, Li Liang
Department of Anaesthesiology, the Second Hospital of Shandong University, No. 247 Beiyuan Street, Jinan, 250033, China.
Department of Breast Surgery, the Second Hospital of Shandong University, No. 247 Beiyuan Street, Jinan, 250033, China.
BMC Anesthesiol. 2018 Oct 20;18(1):145. doi: 10.1186/s12871-018-0608-3.
Postoperative pain is one of the most common symptoms after surgery, which brings physical discomfort to patients. In addition, it may cause a series of complications, and even affect the long-term quality of life. The purpose of this prospective, randomized, double-blinded, controlled trial is to investigate the efficacy and safety of dexmedetomidine combined with sufentanil to attenuate postoperative pain in patients after laparoscopic nephrectomy.
Ninety patients undergoing laparoscopic nephrectomy were randomized into three groups: the control (sufentanil 0.02 μg/kg/h, Group C), sufentanil plus low dose of dexmedetomidine (0.02 μg/kg/h each, Group D1), and sufentanil plus high dose of dexmedetomidine (0.04 μg/kg/h, Group D2). The patient-controlled analgesia was programmed to deliver a bolus dose of 0.5 ml, followed by an infusion of 2 ml/h and a lockout time of 10 min. The primary goal was to calculate the cumulative amount of self-administered sufentanil; the secondary goals were to estimate pain intensity using the numerical rating scale (NRS), level of sedation, the first bowel movement, concerning adverse effects as well as duration of postoperative hospital stay.
The total consumption of sufentanil in group D1 and D2 were significantly lower than in group C during the first 8 h after surgery (P < 0.05), whereas there were no statistically significant differences (P > 0.05) between group D1 and D2. Compared with group C, the NRS scores at rest during first 8 h after surgery were significantly lower in group D1 (P < 0.05). The NRS scores, neither at rest nor with movement, show statistically significant differences between group D1 and D2 at each time point following surgery (P > 0.05). The time to first flatus was shorter in group D1 compared with the control group (P < 0.05). In addition, compared with group C, group D1 and D2 had a shorter time for first defecation (P < 0.05).
Dexmedetomidine combined with sufentanil showed better postoperative analgesia without adverse effects, as well as facilitated bowel movements for patients undergoing laparoscopic nephrectomy.
We registered this study in a Chinese Clinical Trial Registry (ChiCTR) centre on Dec 23 2015 and received the registration number: ChiCTR-IPR-15007628 .
术后疼痛是手术后最常见的症状之一,给患者带来身体不适。此外,它可能会引发一系列并发症,甚至影响长期生活质量。这项前瞻性、随机、双盲、对照试验的目的是研究右美托咪定联合舒芬太尼减轻腹腔镜肾切除术后患者疼痛的有效性和安全性。
90例行腹腔镜肾切除术的患者被随机分为三组:对照组(舒芬太尼0.02μg/kg/h,C组)、舒芬太尼加低剂量右美托咪定组(各0.02μg/kg/h,D1组)和舒芬太尼加 高剂量右美托咪定组(0.04μg/kg/h,D2组)。患者自控镇痛设置为推注剂量0.5ml,随后以2ml/h的速度输注,锁定时间为10分钟。主要目标是计算患者自行使用舒芬太尼的累积量;次要目标是使用数字评分量表(NRS)评估疼痛强度、镇静水平、首次排便情况、不良反应以及术后住院时间。
术后前8小时,D1组和D2组舒芬太尼的总消耗量显著低于C组(P<0.05),而D1组和D2组之间无统计学显著差异(P>0.05)。与C组相比,D1组术后前8小时静息时的NRS评分显著更低(P<0.05)。术后各时间点,D1组和D2组静息及活动时的NRS评分均无统计学显著差异(P>0.05)。D1组首次排气时间比对照组短(P<0.05)。此外,与C组相比,D1组和D2组首次排便时间更短(P<0.05)。
右美托咪定联合舒芬太尼对腹腔镜肾切除术后患者显示出更好的术后镇痛效果且无不良反应,同时促进了肠道蠕动。
我们于2015年12月23日在中国临床试验注册中心(ChiCTR)注册了本研究,注册号为:ChiCTR-IPR-15007628 。